Patent 10945992 was granted and assigned to Tremeau Pharmaceuticals, Inc. on March, 2021 by the United States Patent and Trademark Office.
The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.